TFF Pharmaceuticals (TFFP)
(Real Time Quote from BATS)
$1.74 USD
0.00 (0.00%)
Updated Jul 24, 2024 01:24 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TFFP 1.74 0.00(0.00%)
Will TFFP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TFFP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TFFP
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
TFFP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Other News for TFFP
One new option listing and eighteen option delistings on July 22nd
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
TFF Pharmaceuticals engages Outcome Capital as strategic advisor
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals submits briefing book to the FDA for TFF TAC development